THE WOODLANDS, Texas--(BUSINESS WIRE)--Repros Therapeutics Inc. (NasdaqGM:RPRX) today announces that it has consummated its previously announced sale of an aggregate of 2.4 million shares of its common stock resulting in net proceeds to the Company of approximately $15.5 million after deduction of estimated offering expenses.
